Comparison of edoxaban and enoxaparin in a rat model of AlCl3-induced thrombosis of the superior sagittal sinus

• DOI: 10.1007/s00210-023-02546-x
• Publication Date: 2023-06-01T10:02:27Z
• Authors: M. Hachenberger; M. Yeniguen; L. Suenner; D. Hinchliffe; C. Mueller; A. Wietelmann; T. Gerriets; M. Tschernatsch; M. Juenemann; S. T. Gerner; T. R. Doeppner; H. B. Huttner; T. Braun
• Keywords: Edoxaban; Sinus (botany)

Abstract Cerebral sinus venous thrombosis (CSVT) is an uncommon disease that usually treated with anticoagulation (heparin, low-molecular heparin, or vitamin K-antagonists). We compared treatment edoxaban, oral factor Xa-antagonist, has not been approved in patients CSVT, enoxaparin, a well-established therapy, rat model of CSVT. Fifty male Wistar rats were randomized into 5 groups (10 animals each) and subjected to aluminum chloride (AlCl3)-induced the superior sagittal (SSS) sham procedure. Animals SSS placebo. Diagnostic workup included neurological examination, MRI imaging, MR-flow measurements SSS, immunohistochemical staining. Neurological examination revealed no differences between groups. Seven days after initial thrombosis, flow was lower active group as sham-operated ( p < 0.05). Flow (edoxaban 1 h prior thrombosis: 0.16 cm/s ± 0.06 cm/s; edoxaban 6 0.13 0.05 enoxaparin: 0.04 placebo: 0.07 0.02 cm/s) higher placebo 0.05), but there > Immunohistochemical staining showed actively animals. Edoxaban proved be similar enoxaparin experimental AlCl 3 -induced